TuHURA Biosciences, Inc./NV
Congressional Trades
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
Laurel M. LeeHouse · R · FL |
HURATuHURA Biosciences, Inc./NV · Stock |
Purchase $50,001 - $100,000 |
Aug 9, 2025 | Jul 13, 2025 | Filing ↗ |
Laurel M. LeeHouse · R · FL |
HURATuHURA Biosciences, Inc./NV · Stock |
Purchase $1,001 - $15,000 |
Jan 7, 2025 | Nov 25, 2024 | Filing ↗ |
Laurel M. LeeHouse · R · FL |
HURATuHURA Biosciences, Inc./NV · Cash |
Purchase $100,001 - $250,000 |
May 25, 2024 | May 6, 2024 | Filing ↗ |
Whale Activity
- Increased12
- New7
- Held17
- Decreased38
- Closed17
- No prior filing2
| Filer | Shares | Value | Change |
|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 2.3M | $4.7M | decreased |
| BlackRock, Inc. | 588.2K | $1.2M | decreased |
| FIFTH THIRD BANCORP | 521.6K | $1.1M | new |
| GEODE CAPITAL MANAGEMENT, LLC | 472.8K | $993K | decreased |
| MILLENNIUM MANAGEMENT LLC | 281.3K | $591K | decreased |
| VANGUARD FIDUCIARY TRUST CO | 275.6K | $579K | increased |
| BANK OF AMERICA CORP /DE/ | 246.8K | $518K | increased |
| STATE STREET CORP | 192.6K | $404K | increased |
| Apollon Wealth Management, LLC | 158.1K | $332K | increased |
| Bank of New York Mellon Corp | 111.7K | $234K | decreased |
| AQR CAPITAL MANAGEMENT LLC | 110.9K | $233K | decreased |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 106.7K | $224K | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
No open-market insider buys or sells in the last two years.
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Bianco James A.Chief Executive Officer · Director | Gift | −150.0K | $0.00 | $0 | May 28, 2026 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.7M | $4.1M | 0.00% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 447.7K | $1.0M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 428.5K | $960K | 0.00% | Apr 30, 2026 |
| VANGUARD RUSSELL 2000 INDEX FUND VANGUARD SCOTTSDALE FUNDS | 219.3K | $496K | 0.00% | May 31, 2026 |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 213.0K | $454K | 0.00% | Aug 31, 2026 |
| iShares Micro-Cap ETF iShares Trust | 163.7K | $383K | 0.03% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund SCHWAB CAPITAL TRUST | 98.9K | $222K | 0.00% | Apr 30, 2026 |
| Fidelity Total Market Index Fund Fidelity Concord Street Trust | 76.3K | $162K | 0.00% | Aug 31, 2026 |
| Fidelity Series Total Market Index Fund Fidelity Concord Street Trust | 64.8K | $138K | 0.00% | Aug 31, 2026 |
| VANGUARD RUSSELL 2000 GROWTH INDEX FUND VANGUARD SCOTTSDALE FUNDS | 40.0K | $90K | 0.01% | May 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list HURA's shares (CUSIP 898920103), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Corporate Lobbying
No lobbying filings found naming TuHURA Biosciences, Inc./NV as the client.
Government Contracts
No federal contract awards found for TuHURA Biosciences, Inc./NV.
U.S. Patents
No USPTO patent applications found for TuHURA Biosciences, Inc./NV.
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2024 | FY2023 | FY2023 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | n/a | $0 | n/a |
| Net income | -$30.1M | -$21.7M | -$8.3M | -$29.3M | -$14.6M |
| Diluted EPS | -$0.63 | -$1.21 | n/a | -$2.47 | n/a |
| Operating cash flow | -$27.6M | -$14.7M | -$7.2M | -$12.0M | -$11.9M |
| Cash and equivalents | $3.6M | $12.7M | $4.9M | $3.7M | $1.5M |
| Total assets | $27.4M | $20.0M | $6.2M | $4.4M | $4.0M |
| Total liabilities | $6.4M | $5.4M | $2.4M | $5.9M | $3.2M |
| Shareholders' equity | $20.9M | $14.6M | $3.8M | -$1.6M | $731K |
As TuHURA Biosciences, Inc./NV tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Mar 31, 2026 ↗
Stock Splits
- 1-for-35Reverse splitOct 18, 2024
- 1-for-50Reverse splitNov 14, 2022
- 1-for-10Reverse splitMay 8, 2019
- 1-for-4Reverse splitMay 20, 2016
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
- 8-K · Items 2.03, 9.01Direct financial obligationNov 18, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsNov 13, 2026
EDGAR ↗ - 8-K · Items 2.03, 9.01Direct financial obligationNov 6, 2026
EDGAR ↗ - 8-K · Items 2.03, 9.01Direct financial obligationOct 16, 2026
EDGAR ↗ - 8-K · Items 2.03, 9.01Direct financial obligationSep 24, 2026
EDGAR ↗ - 8-K · Items 2.03, 9.01Direct financial obligationSep 17, 2026
EDGAR ↗ - 8-K/A · Items 5.02, 9.01Officer / director changeSep 17, 2026
EDGAR ↗ - 8-K · Items 5.02, 9.01Officer / director changeSep 16, 2026
EDGAR ↗ - 8-K · Items 2.03, 9.01Direct financial obligationSep 4, 2026
EDGAR ↗ - 8-K · Items 2.03, 9.01Direct financial obligationAug 21, 2026
EDGAR ↗

